A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
The main purpose of this study is to evaluate the safety of the study drug known as LY3039478 in combination with other anticancer agents in participants with advanced or metastatic solid tumors.
Solid Tumor|Breast Cancer|Colon Cancer|Cholangiocarcinoma|Soft Tissue Sarcoma
DRUG: LY3039478|DRUG: Taladegib|DRUG: Abemaciclib|DRUG: Cisplatin|DRUG: Gemcitabine|DRUG: Carboplatin|DRUG: LY3023414
Maximum Tolerated Dose (MTD) of LY3039478, Cycle 1 (up to 28 Days)
Pharmacokinetics (PK): Area Under the Plasma Concentration Time Curve (AUC) of LY3039478 in Combination with Taladegib, LY3023414, Abemaciclib, Cisplatin/Gemcitabine, and Gemcitabine/Carboplatin, Predose Cycle 1 Day 1 through Predose Cycle 2 Day 1 (up to 28 Day Cycles)|PK: AUC of Taladegib and its Active Metabolite LSN3185556, in Combination with LY3039478, Predose Cycle 1 Day 1 through Predose Cycle 2 Day 1 (up to 28 Day Cycles)|PK: AUC of LY3023414 in Combination with LY3039478, Predose Cycle 1 Day 1 through Predose Cycle 2 Day 1 (up to 28 Day Cycles)|PK: AUC of Abemaciclib and its Major Active Metabolites LSN2839567 and LSN3106726, in Combination with LY3039478, Predose Cycle 1 Day 1 through Predose Cycle 2 Day 1 (up to 28 Day Cycles)|Duration of Response (DoR), Date of Complete Response (CR) or Partial Response (PR) to Date of Objective Disease Progression (Estimated up to 12 Months)|Progression Free Survival (PFS), Baseline to Objective Disease Progression or Death (Estimated up to 12 Months)
The main purpose of this study is to evaluate the safety of the study drug known as LY3039478 in combination with other anticancer agents in participants with advanced or metastatic solid tumors.